GlassScriptPhysician profile
Hung T Dang
NPI 1376541656
$7,690.88
in general payments reported to CMS, 2019-2025
52 companies · $672 in 2025
The $672 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,476 · 2020: $765 · 2021: $1,881 · 2022: $1,284 · 2023: $943 · 2024: $670 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,284.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $799.47 | 2019-2024 | Vemlidy |
| Astrazeneca Pharmaceuticals LP | $714.34 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $657.63 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $569.93 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $552.21 | 2019-2025 | Evenity, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $421.67 | 2019-2023 | Belsomra, Gardasil 9, Vaxneuvance |
| Abbvie INC. | $413.49 | 2019-2023 | Creon, Linzess |
| Amarin Pharma, INC. | $358.56 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.80 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $279.52 | 2021-2024 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $241.32 | 2020-2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $197.63 | 2019-2022 | |
| Esperion Therapeutics, INC. | $151.08 | 2021-2024 | Nexletol |
| Pfizer INC. | $140.74 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.09 | 2021-2023 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hung Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.